Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Bone Remodeling in an Mps-1h Girl after Hematopoietic Stem Cell Transplantation along with Enzymatic Replacement Therapy

Author(s): Albina Tummolo*, Giacomina Brunetti, Laura Piacente, Antonio Marzollo, Alessandra Biffi, Alberto Burlina and Maria Felicia Faienza

Volume 22, Issue 14, 2022

Published on: 05 August, 2022

Page: [1425 - 1432] Pages: 8

DOI: 10.2174/1871530322666220520121839

Price: $65

Abstract

Background: Mucopolysaccharidosis-1H (Hurler syndrome, MPS-1H) is the most severe form of a lysosomal storage disorder (LSD) caused by variants in IDUA, encoding alpha- L-iduronidase (IDUA). MPS-1H is also associated with various degrees of skeletal defects due to the accumulation of partially degraded glycosaminoglycans (GAGs) in the lysosomes of connective tissue cells. The efficacy of hematopoietic stem cell transplantation (HSCT) and enzymatic replacement therapy (ERT) on MPS-1H skeletal manifestations is still considered unsatisfactory.

Case Presentation: We report the case of a young girl, who manifested significant changes in bone remodeling markers and osteoclastogenesis potential after HSCT combined with ERT. She received ERT and underwent two HSCTs. The skeletal alterations at the time of diagnosis showed a trend toward improvement of both mobility and radiological features after HSCT. We observed the highest levels of Receptor activator of nuclear factor-kappa-Β ligand (RANKL) and RANK/osteoprotegerin (OPG) ratio at diagnosis and during ERT, consistently with spontaneous osteoclastogenesis. Conversely, after the successful HSCT with ongoing ERT, the highest levels of osteocalcin were observed and all markers of bone formation and resorption improved.

Conclusion: The combination therapy of ERT and HSCT was effective in reducing osteoclast activity and increasing osteoblast activity, and these changes were according to the child's bone phenotype, IDUA activity, and Glycosaminoglycan (GAG) trends. These results represent one of the few pieces of human evidence in this context.

Keywords: HSCT, ERT, mps-1h, osteoclastogenesis, rankl, glycosaminoglycan.

« Previous Next »
Graphical Abstract

[1]
Neufeld, E.; Muenzer, J. The mucopolysaccharidoses. In: Scriver, C.; Beaudet, A.; Sly, W.S.; Valle, D.; Eds. The Metabolic and Molecular Bases of Inherited Disease, 8th Ed; McGraw-Hill: New York, 2001, pp. 3421-3452.
[2]
White, K.K. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford), 2011, 50(Suppl. 5), v26-v33.
[http://dx.doi.org/10.1093/rheumatology/ker393] [PMID: 22210667]
[3]
Stevenson, D.A.; Rudser, K.; Kunin-Batson, A.; Fung, E.B.; Viskochil, D.; Shapiro, E.; Orchard, P.J.; Whitley, C.B.; Polgreen, L.E. Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. J. Pediatr. Rehabil. Med., 2014, 7(2), 159-165.
[http://dx.doi.org/10.3233/PRM-140285] [PMID: 25096868]
[4]
Muenzer, J.; Bodamer, O.; Burton, B.; Clarke, L.; Frenking, G.S.; Giugliani, R.; Jones, S.; Rojas, M.V.M.; Scarpa, M.; Beck, M.; Harmatz, P. The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur. J. Pediatr., 2012, 171(1), 181-188.
[http://dx.doi.org/10.1007/s00431-011-1606-3] [PMID: 22037758]
[5]
Lachmann, R.H. Treating lysosomal storage disorders: What have we learnt? J. Inherit. Metab. Dis., 2020, 43(1), 125-132.
[http://dx.doi.org/10.1002/jimd.12131] [PMID: 31140601]
[6]
Peters, C.; Shapiro, E.G.; Anderson, J.; Henslee-Downey, P.J.; Klemperer, M.R.; Cowan, M.J.; Saunders, E.F.; deAlarcon, P.A.; Twist, C.; Nachman, J.B.; Hale, G.A.; Harris, R.E.; Rozans, M.K.; Kurtzberg, J.; Grayson, G.H.; Williams, T.E.; Lenarsky, C.; Wagner, J.E.; Krivit, W. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood, 1998, 91(7), 2601-2608.
[http://dx.doi.org/10.1182/blood.V91.7.2601] [PMID: 9516162]
[7]
Staba, S.L.; Escolar, M.L.; Poe, M.; Kim, Y.; Martin, P.L.; Szabolcs, P.; Allison-Thacker, J.; Wood, S.; Wenger, D.A.; Rubinstein, P.; Hopwood, J.J.; Krivit, W.; Kurtzberg, J. Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. N. Engl. J. Med., 2004, 350(19), 1960-1969.
[http://dx.doi.org/10.1056/NEJMoa032613] [PMID: 15128896]
[8]
Masterson, E.L.; Murphy, P.G.; O’Meara, A.; Moore, D.P.; Dowling, F.E.; Fogarty, E.E. Hip dysplasia in Hurler’s syndrome: Orthopaedic management after bone marrow transplantation. J. Pediatr. Orthop., 1996, 16(6), 731-733.
[http://dx.doi.org/10.1097/01241398-199611000-00006] [PMID: 8906643]
[9]
Odunusi, E.; Peters, C.; Krivit, W.; Ogilvie, J. Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: Correction by surgical intervention. J. Pediatr. Orthop., 1999, 19(2), 270-274.
[http://dx.doi.org/10.1097/01241398-199903000-00026] [PMID: 10088702]
[10]
Van Heest, A.E.; House, J.; Krivit, W.; Walker, K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J. Hand Surg. Am., 1998, 23(2), 236-243.
[http://dx.doi.org/10.1016/S0363-5023(98)80120-2] [PMID: 9556262]
[11]
Gatto, F.; Redaelli, D.; Salvadè, A.; Marzorati, S.; Sacchetti, B.; Ferina, C.; Roobrouck, V.D.; Bertola, F.; Romano, M.; Villani, G.; Antolini, L.; Rovelli, A.; Verfaillie, C.M.; Biondi, A.; Riminucci, M.; Bianco, P.; Serafini, M. Hurler disease bone marrow stromal cells exhibit altered ability to support osteoclast formation. Stem Cells Dev., 2012, 21(9), 1466-1477.
[http://dx.doi.org/10.1089/scd.2011.0555]
[12]
Bunge, S.; Kleijer, W.J.; Steglich, C.; Beck, M.; Zuther, C.; Morris, C.P.; Schwinger, E.; Hopwood, J.J.; Scott, H.S.; Gal, A. Mucopolysaccharidosis type I: Identification of 8 novel mutations and determination of the frequency of the two common alpha-L-iduronidase mutations (W402X and Q70X) among European patients. Hum. Mol. Genet., 1994, 3(6), 861-866.
[http://dx.doi.org/10.1093/hmg/3.6.861] [PMID: 7951228]
[13]
Scott, H.S.; Litjens, T.; Nelson, P.V.; Brooks, D.A.; Hopwood, J.J.; Morris, C.P. alpha-L-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. Hum. Mutat., 1992, 1(4), 333-339.
[http://dx.doi.org/10.1002/humu.1380010412] [PMID: 1301941]
[14]
Corbo, F.; Brunetti, G.; Crupi, P.; Bortolotti, S.; Storlino, G.; Piacente, L.; Carocci, A.; Catalano, A.; Milani, G.; Colaianni, G.; Colucci, S.; Grano, M.; Franchini, C.; Clodoveo, M.L.; D’Amato, G.; Faienza, M.F. Effects of sweet cherry polyphenols on enhanced osteoclastogenesis associated with childhood obesity. Front. Immunol., 2019, 10, 1001.
[http://dx.doi.org/10.3389/fimmu.2019.01001] [PMID: 31130968]
[15]
Vartanyan, A.; Montaño, A.M. Causal therapies in mucopolysaccharidoses: Enzyme replacement therapy. J. Child. Sci., 2018, 8(1), e156-e162.
[http://dx.doi.org/10.1055/s-0038-1667346]
[16]
Do Cao, J.; Wiedemann, A.; Quinaux, T.; Battaglia-Hsu, S.F.; Mainard, L.; Froissart, R.; Bonnemains, C.; Ragot, S.; Leheup, B.; Journeau, P.; Feillet, F. 30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case. Mol. Genet. Metab. Rep., 2016, 9, 42-45.
[http://dx.doi.org/10.1016/j.ymgmr.2016.10.001] [PMID: 27761411]
[17]
Taylor, M.; Khan, S.; Stapleton, M.; Wang, J.; Chen, J.; Wynn, R.; Yabe, H.; Chinen, Y.; Boelens, J.J.; Mason, R.W.; Kubaski, F.; Horovitz, D.D.G.; Barth, A.L.; Serafini, M.; Bernardo, M.E.; Kobayashi, H.; Orii, K.E.; Suzuki, Y.; Orii, T.; Tomatsu, S. Hematopoietic stem cell transplantation for mucopolysaccharidoses: Past, present, and future. Biol. Blood Marrow Transplant., 2019, 25(7), e226-e246.
[http://dx.doi.org/10.1016/j.bbmt.2019.02.012] [PMID: 30772512]
[18]
Yasuda, E.; Mackenzie, W.; Ruhnke, K.; Shimada, T.; Mason, R.W.; Zustin, J.; Martin, P.L.; Thacker, M.; Orii, T.; Sai, Y.; Tomatsu, S. Molecular genetics and metabolism report long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: Clinical, biochemical, and pathological improvements. Mol. Genet. Metab. Rep., 2015, 2, 65-76.
[http://dx.doi.org/10.1016/j.ymgmr.2014.12.006] [PMID: 25709894]
[19]
Kuehn, S.C.; Koehne, T.; Cornils, K.; Markmann, S.; Riedel, C.; Pestka, J.M.; Schweizer, M.; Baldauf, C.; Yorgan, T.A.; Krause, M.; Keller, J.; Neven, M.; Breyer, S.; Stuecker, R.; Muschol, N.; Busse, B.; Braulke, T.; Fehse, B.; Amling, M.; Schinke, T. Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I. Hum. Mol. Genet., 2015, 24(24), 7075-7086.
[http://dx.doi.org/10.1093/hmg/ddv407] [PMID: 26427607]
[20]
Santi, L.; De Ponti, G.; Dina, G.; Pievani, A.; Corsi, A.; Riminucci, M.; Khan, S.; Sawamoto, K.; Antolini, L.; Gregori, S.; Annoni, A.; Biondi, A.; Quattrini, A.; Tomatsu, S.; Serafini, M. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model. Mol. Genet. Metab., 2020, 130(3), 197-208.
[http://dx.doi.org/10.1016/j.ymgme.2020.05.001] [PMID: 32439268]

Rights & Permissions Print Cite
Article Metrics
21
3
Wayfinder Image
World Diabetes Day
© 2024 Bentham Science Publishers | Privacy Policy